Gefnest
RACE......
is against Time
Expert's View
- Gefitinib significantly outperformed erlotinib and should therefore be the EGFR-TKI of choice in platinum-pretreated relapsed NSCLC.
- Gefitinib a significantly increased progression-free survival (PFS) [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.50-0.76, |(2) = 78.1%] and overall survival (HR 0.84, 95% CI 0.76-0.93, |(2) = 0.0%)
- Getitinib deserves consideration as a primary treatment for EGFR-mutant NSCLC.
-
The gefitinib group had a significantly longer median progression-free survival (10.8 months, vs. 5.4 months in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P < 0.001),as well as a higher response rate (73.7% vs. 30.7%, p < 0.001).
- Getitinib as monotherapy is an effective treatment for patients with locally advanced or metastatic NSCLC with EGFR mutations.
- Getitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers.
Recommended In
- Non-Small Cell Lung Cancer ( NSCLC)
- Breast Cancer
- Colon Cancer
-
Adenocarcinoma
